Ciphergen Biosystems, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Proposed initial public offering of up to $86.3 mil. in common stock would fund expanded sales and marketing capabilities, R&D and corporate facilities, according to a preliminary prospectus filed with the Securities and Exchange Commission. The Palo Alto, California-based firm's ProteinChip protein analysis tool enables protein discovery, characterization and assay development for the protein-based biology research market. The current Series PBS II ProteinChip system debuted in May 1999. Ciphergen has 60 employees and in 1999 recorded sales of $5 mil., up 70.8%. A net loss of $7.7 mil. for the year compares to a loss of $8.3 mil. in 1998. The IPO is being underwritten by SG Cowen, ING Barings and Warburg Dillon Read
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.